Our long-term goal is to develop a natural hepatic scaffold with multi-cellular cues for complete and stable maturation of stem-derived liver cells to engineer functional livers in vitro and use them for modeling liver steatosis and therapeutics. The objectives of the proposed study are to develop an organ culture system for liver engineering with induced pluripotent stem (iPS) cell-derived liver cells, and investigate its employment to understand pathogenesis, natural history and development of early detection tools and treatments for fatty liver diseases. The central hypothesis to be tested here is that the decellularized natural liver scaffold can be extensively repopulated, will provide a stable organ-like environment for the metabolic maturation of iPS derived liver cells, and may be used as an approach to induce formation of functional mini-livers using human wild type iPS cells or iPS cells after genetic engineer for fatty liver disease by knockdown of SIRT1 and/or (key gene implicated with liver steatosis formation). The rationale for the proposed research is that, once human liver tissue with multi-cellular cues can be reproducibly manufactured in vitro with normal and disease phenotypes, development of liver steatosis can be manipulated pharmacologically, resulting in new and innovative approaches to the prevention and treatment of a variety liver disease. The work described here is expected to i) generate a metabolic maturation system for human iPS cell-derived liver cells to form tissue, ii) establish human iPS cells carrying shRNA mediated conditional knockdown of SIRT1 and iii) develop a novel approach for modeling an organ-like environment to determine the role of SIRT1 in human liver steatosis or fatty liver disease. The results of this work will also have a positive impact by establishing the basis and platform for future sophisticated organ engineering techniques that incorporates several different cell types and may lead to development of entire organs in vitro, these techniques could be applied to study other liver diseases (e.g. metabolic diseases) and is expected to be a major contribution to the fields of stem cells engineering and liver steatosis.

Public Health Relevance

Liver diseases cause about 28,000 deaths annually in the US, and the progression of fatty liver (nonalcoholic steatohepatitis, NASH) is the most common cause of liver dysfunction worldwide. To date the factors that promote fat deposition in the liver and the transition from steatosis to NASH and cirrhosis in humans are unknown. One obstacle to study such pathological transition is the absence of appropriate human liver tissue model. This project aims to improve public health by utilizing organ engineering technology and stem cell engineering to constitute mini-livers that mimic human fatty liver disease with success.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK099257-02
Application #
8897365
Study Section
Bioengineering, Technology and Surgical Sciences Study Section (BTSS)
Program Officer
Doo, Edward
Project Start
2014-08-01
Project End
2018-07-31
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
2
Fiscal Year
2015
Total Cost
$334,950
Indirect Cost
$117,450
Name
University of Pittsburgh
Department
Pathology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Chen, Chen; Soto-Gutierrez, Alejandro; Baptista, Pedro M et al. (2018) Biotechnology Challenges to In Vitro Maturation of Hepatic Stem Cells. Gastroenterology 154:1258-1272
Agarwal, Nandini; Popovic, Branimir; Martucci, Nicole J et al. (2018) Biofabrication of Autologous Human Hepatocytes for Transplantation: How do we get there? Gene Expr :
Guzman-Lepe, Jorge; Cervantes-Alvarez, Eduardo; Collin de l'Hortet, Alexandra et al. (2018) Liver-enriched transcription factor expression relates to chronic hepatic failure in humans. Hepatol Commun 2:582-594
Marré, Meghan L; Piganelli, Jon D; James, Eddie A (2018) Protecting functional ? cells with a therapeutic peptide. Ann Transl Med 6:372
Dubaisi, Sarah; Barrett, Kathleen G; Fang, Hailin et al. (2018) Regulation of Cytosolic Sulfotransferases in Models of Human Hepatocyte Development. Drug Metab Dispos 46:1146-1156
Soltys, Kyle A; Setoyama, Kentaro; Tafaleng, Edgar N et al. (2017) Host conditioning and rejection monitoring in hepatocyte transplantation in humans. J Hepatol 66:987-1000
Soto-Gutierrez, Alejandro; Gough, Albert; Vernetti, Lawrence A et al. (2017) Pre-clinical and clinical investigations of metabolic zonation in liver diseases: The potential of microphysiology systems. Exp Biol Med (Maywood) 242:1605-1616
Squires, James E; Soltys, Kyle A; McKiernan, Patrick et al. (2017) Clinical Hepatocyte Transplantation: What Is Next? Curr Transplant Rep 4:280-289
Ono, Yoshihiro; Pérez-Gutiérrez, Angelica; Yovchev, Mladen I et al. (2017) Regeneration and Cell Recruitment in an Improved Heterotopic Auxiliary Partial Liver Transplantation Model in the Rat. Transplantation 101:92-100
Tobita, Takamasa; Guzman-Lepe, Jorge; Takeishi, Kazuki et al. (2016) SIRT1 Disruption in Human Fetal Hepatocytes Leads to Increased Accumulation of Glucose and Lipids. PLoS One 11:e0149344

Showing the most recent 10 out of 13 publications